Canadian trade group changes name to Innovative Medicines Canada

7 January 2016

Ringing in the New Year with a new name, Canada’s Research-Based Pharmaceutical Companies (Rx&D) is changing its brand to become Innovative Medicines Canada to better reflect its values and mandate.

“Our everyday work is reflected in our new brand, and we’re very excited to unveil this new name to Canadians,” said Russell Williams, president of Innovative Medicines Canada, adding: “Innovation is not only what we do, but also how we do things. Along with our members, we are pushing the boundaries in how we deal with illnesses, how we work with our partners and how we demonstrate the value of innovative medicines and vaccines.”

Following an extensive consultation and engagement with key stakeholders and partners in the life sciences community, Rx&D developed a new brand that better aligns with its values and work and resonates with all partners.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK